JP2016536372A5 - - Google Patents

Download PDF

Info

Publication number
JP2016536372A5
JP2016536372A5 JP2016553225A JP2016553225A JP2016536372A5 JP 2016536372 A5 JP2016536372 A5 JP 2016536372A5 JP 2016553225 A JP2016553225 A JP 2016553225A JP 2016553225 A JP2016553225 A JP 2016553225A JP 2016536372 A5 JP2016536372 A5 JP 2016536372A5
Authority
JP
Japan
Prior art keywords
substituted
residue
hydrogen
alkyl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016553225A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016536372A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/064028 external-priority patent/WO2015069699A1/en
Publication of JP2016536372A publication Critical patent/JP2016536372A/ja
Publication of JP2016536372A5 publication Critical patent/JP2016536372A5/ja
Pending legal-status Critical Current

Links

JP2016553225A 2013-11-05 2014-11-05 クレアチン類似体及びその使用 Pending JP2016536372A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361899975P 2013-11-05 2013-11-05
US61/899,975 2013-11-05
PCT/US2014/064028 WO2015069699A1 (en) 2013-11-05 2014-11-05 Creatine analogs and the use thereof

Publications (2)

Publication Number Publication Date
JP2016536372A JP2016536372A (ja) 2016-11-24
JP2016536372A5 true JP2016536372A5 (enExample) 2017-10-19

Family

ID=53042015

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016553225A Pending JP2016536372A (ja) 2013-11-05 2014-11-05 クレアチン類似体及びその使用

Country Status (6)

Country Link
US (1) US20160289175A1 (enExample)
EP (1) EP3065726A4 (enExample)
JP (1) JP2016536372A (enExample)
AU (1) AU2014346952A1 (enExample)
CA (1) CA2929538A1 (enExample)
WO (1) WO2015069699A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9617230B2 (en) 2014-12-22 2017-04-11 Farmington Pharma Development Creatine prodrugs, compositions and methods of use thereof
WO2016110822A1 (en) * 2015-01-09 2016-07-14 Universita' Degli Studi Di Genova Carboxylic biacyl creatine derivative, uses and method of synthesis thereof
US11021501B2 (en) 2015-03-30 2021-06-01 Farmington Pharma Development Creatine phosphate analog prodrugs, compositions and methods of use thereof
WO2019109067A2 (en) * 2017-12-01 2019-06-06 Ultragenyx Pharmaceutical Inc. Creatine prodrugs, compositions and methods of use thereof
IL297503A (en) * 2020-04-23 2022-12-01 Pan Dipanjan Components of self-assembled oxygen carriers

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03002068A (es) * 2000-09-14 2004-09-10 Univ Nebraska Compuestos y formulaciones pro-nutrientes de ester de creatina.
US7125568B2 (en) * 2001-08-23 2006-10-24 Sung Michael T Lipophilic drug compositions
EP1567180A4 (en) * 2002-06-04 2010-03-10 Avicena Group Inc METHODS OF TREATING COGNITIVE DYSFUNCTIONS BY MODULATING BRAIN ENERGY METABOLISM
US20080103202A1 (en) * 2004-11-08 2008-05-01 Chris Ferguson Method of preparing creatine ester salts and uses thereof.
US20070281995A1 (en) * 2006-06-06 2007-12-06 Xenoport, Inc. Creatine analog prodrugs, compositions and uses thereof
US20080206170A1 (en) * 2006-12-07 2008-08-28 Belinda Tsao Nivaggioli Creatine compositions for skin treatment
US7314945B1 (en) * 2007-02-20 2008-01-01 Multi Formulations Ltd. Creatine-fatty acids
WO2008101310A1 (en) * 2007-02-20 2008-08-28 Multi Formulations Ltd. Creatine-fatty acids
US8426395B2 (en) * 2008-05-30 2013-04-23 Northern Northern Innovations Holding Corp Preparations containing creatine and imino sugars
US8350077B2 (en) * 2008-12-24 2013-01-08 Vertex Closed Joint Stock Company Amides of creatine, method of their preparation, and remedy possessing a neuroprotective activity
US20100215707A1 (en) * 2009-02-25 2010-08-26 Mcdonald Thomas Activated creatinine and precursors thereof as antibacterial agents, compositions and products containing such agents and uses thereof
RU2428414C2 (ru) * 2009-11-03 2011-09-10 Закрытое Акционерное Общество "Вертекс" Способ получения амидов креатина
US8445466B2 (en) * 2010-04-08 2013-05-21 John H. Owoc Stable aqueous compositions comprising amide-protected bioactive creatine species and uses thereof
AU2012312654B2 (en) * 2011-09-19 2017-04-13 Gencia Corporation Modified creatine compounds
EP2692719B1 (en) * 2012-07-30 2016-06-08 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Method for preparing creatine fatty esters, creatine fatty esters thus prepared and uses thereof

Similar Documents

Publication Publication Date Title
KR102666477B1 (ko) 글루타민 유사체의 프로드럭
JP2016536372A5 (enExample)
JP2018016629A5 (enExample)
JP2016153410A5 (enExample)
AU2010208071C1 (en) Cyclosporin analogues for preventing or treating hepatitis C infection
JP2008509166A5 (enExample)
JP2010508362A5 (enExample)
US8481483B2 (en) Cyclosporin analogues
JP2010508361A5 (enExample)
JP2019514426A5 (enExample)
JP2008522981A5 (enExample)
JP2013537907A5 (enExample)
JP2012512898A5 (enExample)
JP2018528261A5 (enExample)
JP2009538348A5 (enExample)
JP2013537195A5 (ja) 疾患を治療するための医薬品及び同医薬品を含むキット
CN105814028A (zh) 作为免疫调节剂的1,2,4-*二唑衍生物
JP2015024998A5 (enExample)
JP2010514768A5 (enExample)
JP2013511554A5 (enExample)
JP2013155195A5 (enExample)
JP2009504763A5 (enExample)
JP2008501637A5 (enExample)
JP2008512490A5 (enExample)
JP2012509846A5 (enExample)